These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14708714)

  • 41. The functionality of HLA-G is emerging.
    Le Bouteiller P; Blaschitz A
    Immunol Rev; 1999 Feb; 167():233-44. PubMed ID: 10319265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune modulation of HLA-G dimer in maternal-fetal interface.
    Kuroki K; Maenaka K
    Eur J Immunol; 2007 Jul; 37(7):1727-9. PubMed ID: 17587197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice.
    Horuzsko A; Lenfant F; Munn DH; Mellor AL
    Int Immunol; 2001 Mar; 13(3):385-94. PubMed ID: 11222508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Placental HLA-G protein expression in vivo: where and what for?
    Le Bouteiller P; Solier C; Pröll J; Aguerre-Girr M; Fournel S; Lenfant F
    Hum Reprod Update; 1999; 5(3):223-33. PubMed ID: 10438107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells.
    Münz C; Holmes N; King A; Loke YW; Colonna M; Schild H; Rammensee HG
    J Exp Med; 1997 Feb; 185(3):385-91. PubMed ID: 9053439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HLA-G remains a mystery.
    Bainbridge D; Ellis S; Le Bouteiller P; Sargent I
    Trends Immunol; 2001 Oct; 22(10):548-52. PubMed ID: 11574277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microglia and central nervous system immunity.
    Kaur G; Han SJ; Yang I; Crane C
    Neurosurg Clin N Am; 2010 Jan; 21(1):43-51. PubMed ID: 19944965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HLA-G functions as a restriction element and a transplantation antigen in mice.
    Horuzsko A; Antoniou J; Tomlinson P; Portik-Dobos V; Mellor AL
    Int Immunol; 1997 May; 9(5):645-53. PubMed ID: 9184910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stranger in a strange land.
    Hunt JS
    Immunol Rev; 2006 Oct; 213():36-47. PubMed ID: 16972895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of HLA-G in human cornea, an immune-privileged tissue.
    Le Discorde M; Moreau P; Sabatier P; Legeais JM; Carosella ED
    Hum Immunol; 2003 Nov; 64(11):1039-44. PubMed ID: 14602233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble HLA-G: Are they clinically relevant?
    Pistoia V; Morandi F; Wang X; Ferrone S
    Semin Cancer Biol; 2007 Dec; 17(6):469-79. PubMed ID: 17825579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?
    Kren L; Muckova K; Lzicarova E; Sova M; Vybihal V; Svoboda T; Fadrus P; Smrcka M; Slaby O; Lakomy R; Vanhara P; Krenova Z; Michalek J
    J Neuroimmunol; 2010 Mar; 220(1-2):131-5. PubMed ID: 20167379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cellular immunity and immunotherapy of brain tumors.
    Prins RM; Liau LM
    Front Biosci; 2004 Sep; 9():3124-36. PubMed ID: 15353342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HLA-G inhibits the allogeneic proliferative response.
    Riteau B; Menier C; Khalil-Daher I; Sedlik C; Dausset J; Rouas-Freiss N; Carosella ED
    J Reprod Immunol; 1999 Jul; 43(2):203-11. PubMed ID: 10479056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
    Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
    Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes.
    Le Friec G; Laupèze B; Fardel O; Sebti Y; Pangault C; Guilloux V; Beauplet A; Fauchet R; Amiot L
    Hum Immunol; 2003 Aug; 64(8):752-61. PubMed ID: 12878353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.
    Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P
    J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA-G protein expression is not induced during malignant transformation.
    Pangault C; Amiot L; Caulet-Maugendre S; Brasseur F; Burtin F; Guilloux V; Drenou B; Fauchet R; Onno M
    Tissue Antigens; 1999 Apr; 53(4 Pt 1):335-46. PubMed ID: 10323337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.